Literature DB >> 561758

An abnormal luteal-phase evening peak of plasma prolactin in women with a family history of breast cancer.

H G Kwa, D Y Wang.   

Abstract

In earlier study an abnormally high lutealphase evening peak of plasma prolactin in women with a family history of breast cancer was first noted, but there were few observations. The current study confirms the original findings. Other groups, e.g. nulliparous women and tall and heavy women also appear to show the same abnormality. Further work is required to establish this finding. However, the abnormally high luteal-phase evening peak of plasma prolactin in the family history group is still present when such women are disregarded. The possible relevance of the restriction of elevated prolactin levels, in enhanced-risk women, to the luteal phase, when both oestradiol and progresterone levels are also elevated, is discussed briefly as is the question why a minor peak at 19.00 h is important when plasma prolactin levels show a massive increase between 03.00 and 09.00 h.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 561758     DOI: 10.1002/ijc.2910200104

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Cigarette smoking and prolactin in women.

Authors:  J A Baron; R D Bulbrook; D Y Wang; H G Kwa
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-23

Review 2.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

3.  Energy balance, early life body size, and plasma prolactin levels in postmenopausal women.

Authors:  Xuefen Su; Susan E Hankinson; Charles V Clevenger; A Heather Eliassen; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2008-10-14       Impact factor: 2.506

4.  Breast cancer in a male patient with prolactinoma.

Authors:  S Haga; O Watanabe; T Shimizu; T Iida; H Imamura; T Kajiwara; M Fujibayashi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer.

Authors:  P F Bruning; J G Bonfrèr; E Engelsman; E Hamersma-vd Linden; M de Jong-Bakker; W Nooyen
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

Review 6.  Prolactin and breast cancer etiology: an epidemiologic perspective.

Authors:  Shelley S Tworoger; Susan E Hankinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

7.  Plasma lipids and prolactin in patients with breast cancer.

Authors:  I A Bani; C M Williams; P S Boulter; J W Dickerson
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.